outcomes in rrmm: the modern treatment paradigm and bcma
Published 4 years ago • 96 plays • Length 6:09Download video MP4
Download video MP3
Similar videos
-
4:15
what’s next for bcma-targeted adcs and car-t therapy in rrmm?
-
55:48
hitting the bcma target in multiple myeloma
-
3:19
bcma-targeted therapy in rrmm: results from the dreamm-1 trial
-
6:01
免疫治疗-十年来癌症治疗重大突破(下)
-
40:06
multiple myeloma: a pathway to better outcomes
-
47:18
diagnosis and risk assessment in multiple myeloma
-
3:47
bcma-targeted therapy in rrmm: future challenges and bite
-
0:53
incorporating bcma-targeted car-t therapy in the frontline treatment of multiple myeloma
-
1:29
improving outcomes of bcma-targeting adcs in multiple myeloma
-
54:38
bcma antibodies and cellular therapies in rrmm
-
3:41
moving bcma-targeted agents to the frontline setting in myeloma & sequencing immunotherapies
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
5:24
bcma-targeted therapy in rrmm: management of adverse events
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
2:31
integrating bcma-targeted agents in earlier lines of therapy for r/r multiple myeloma
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
58:19
sequencing bcma myeloma therapies
-
1:48
mechanisms behind the loss of bcma in multiple myeloma & options for patients
-
3:28
the importance of bcma-targeting adcs and bispecific antibodies in r/r multiple myeloma
-
1:30
managing the challenges associated with continuous bcma-directed therapy in multiple myeloma
-
4:43
potential sequencing of bcma-directed therapies in rrmm